Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | PTGIS | Q16647 | 1/20 | 0.44 |
| ▸ | ADH5 | P11766 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9265699 | 0.98 | SRC (0.48) | SRCIDO1CYP11B2TBXAS1MKNK1 | |
| SCHEMBL2354076 | 0.87 | IDO1 (0.48) | IDO1CYP11B2TBXAS1MKNK1MKNK2 | |
| SCHEMBL3536508 | 0.82 | CYP11B2 (0.55) | SRCIDO1CYP11B2TBXAS1PTGS1 | |
| Hydrochloric Acid SCHEMBL3537661 | 0.81 | CYP11B2 (0.54) | SRCIDO1CYP11B2TBXAS1PTGS1 | |
| SCHEMBL10650910 | 0.79 | TBXAS1 (0.55) | TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL10648250 | 0.79 | TBXAS1 (0.55) | CYP11B2TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL10652058 | 0.78 | CYP11B2 (0.50) | SRCIDO1CYP11B2TBXAS1PTGS1 | |
| SCHEMBL10645953 | 0.77 | TBXAS1 (0.48) | IDO1CYP11B2TBXAS1PTGS1PTGS2 | |
| SCHEMBL10650048 | 0.77 | TBXAS1 (0.41) | IDO1CYP11B2TBXAS1PTGS1PTGS2 | |
| SCHEMBL10645946 | 0.77 | TBXAS1 (0.48) | IDO1CYP11B2TBXAS1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | claimed |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | UNIVERSITY OF MASSACHUSETTS (US) | 2026-03-31 | — | — | US | disclosed |
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8008333-B2 | Inducing ovulation; increasing response to follicle stimulating hormone | ARES TRADING S.A. (CH) | 2011-08-30 | — | — | US | disclosed |
| US-7820706-B2 | Multiple dose aromatase inhibitor for treating infertility | ARES TRADING S.A. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CASPER ROBERT F | 2010-04-29 | — | — | US | disclosed |
| EP-1898923-A4 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | CASPER ROBERT F (CA) | 2009-05-20 | — | — | EP | disclosed |
| EP-1804805-A4 | USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY | UNIV WAYNE STATE (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1898923-A1 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | Casper, Robert F. (CA) | 2008-03-19 | — | — | EP | disclosed |
| EP-0366609-B1 | Use of bicyclic imidazole derivatives in treating hyperaldosteronism | CIBA GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
| US-5057521-A | USE OF BICYCLIC IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HYPERALDOSTERONISM | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0165904-B1 | SUBSTITUTED BICYCLE COMPOUNDS | CIBA-GEIGY AG (CH) | 1991-04-10 | — | — | EP | disclosed |
| EP-0366609-A2 | Use of bicyclic imidazole derivatives in treating hyperaldosteronism | CIBA-GEIGY AG (CH) | 1990-05-02 | — | — | EP | disclosed |
| US-4889861-A | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors | CIBA-GEIGY CORP. (US) | 1989-12-26 | — | — | US | disclosed |
| EP-0114573-B1 | IMIDAZO(1,5-A)PYRIDINE DERIVATIVES | CIBA-GEIGY AG (CH) | 1988-04-20 | — | — | EP | disclosed |
| US-4728645-A | THROMBOXANE SYNTHETASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1988-03-01 | — | — | US | disclosed |
| US-4617307-A | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors | CIBA-GEIGY CORPORATION (US) | 1986-10-14 | — | — | US | disclosed |
| US-4588732-A | Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors | CIBA-GEIGY CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0165904-A2 | Substituted bicycle compounds | CIBA-GEIGY AG (CH) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CYP19A1, SHBG, HSD17B11 | SRC 1971/4885IDO1 1027/4885CYP11B2 25/4885 |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | ESR1, ESR2, ESRRA | SRC 2938/4885IDO1 4784/4885CYP11B2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.